EMET Pharmaceuticals, LLC Report issue

For profit Phase 3
Founded: Amityville NY United States (2003)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2008
NCT01045018
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

mesalamine (rowasa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1